Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

A Study to Describe the Incidence Rate and Clinical Features of Human Meta Pneumovirus (hMPV) Infection of the Lower Respiratory Tract in Hospitalized Children at High Risk for Severe Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00192439

Enrollment

1500

Registered

2005-09-19

Start date

2003-12-31

Completion date

2006-12-31

Last updated

2007-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Respiratory Disease

Brief summary

\- Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash aspirates in children at high risk for severe LRI disease (hospitalized at \<2 years of age).

Detailed description

* A prospective, epdemiological study to estimate the incidence rate of hMPV infection as determined by RT-PCR from frozen nasal wash aspirates taken from children hospitalized with LRI who are at high risk for severe disease. * No study drug will be administered for this study.

Interventions

BEHAVIORALHigh Risk Respiratory Disease

Study design

Observational model

DEFINED_POPULATION

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

1 Days to 24 Months

Healthy volunteers

Inclusion criteria

* Be premature (less than 36 weeks gestation) and less than or equal to 12 months of age, and/or * Be less than or equal to 24 months of age with CHD (other than uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus) that is judged to be hemodynamically significant, and/or * Be less than or equal to 24 months of age with CLD of prematurity (BPD) requiring medical intervention/management (i.e., supplemental oxygen, steroids, bronchodilators, or diuretics within the previous 6 months). * Hospital admission diagnosis referable to an acute lower respiratory tract infection or cardio/respiratory illness with a presumed respiratory infection (e.g., bronchiolitis, bronchitis, or pneumonia or cardiac decompensation associated with respiratory infection); admission must occur between October 1 and June 30 for northern hemisphere sites, and between March 1 and November 30 for southern hemisphere sites. * Study enrollment within 2 days after hospitalization. * Admission from the community to the Pediatric ward, Neonatal Intensive Care Unit, or the Intensive Care Unit. * Have written informed consent obtained from the parent or legal guardian prior to study entry.

Exclusion criteria

* Known HIV infection or a mother with known HIV infection.

Countries

Australia, Canada, Italy, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026